Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2023) - Biocure Technology Inc. (CSE: CURE) ("CURE" or the "Company") announces that it has entered into an exclusive letter agreement dated September 8, 2023 with Atriva Therapeutics GmbH. ("Atriva") whereby the Company will acquire all of the issued and outstanding securities of Atriva (the "Transaction"). The Transaction will be a business combination completed by way of a share exchange, share purchase, amalgamation,...
2023-09-18 9:00 AM EDT
Biocure Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 25, 2022) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) ("Biocure" or the "Company") is pleased to provide the following operational and investment update to the market and its stakeholders. BPK is currently under way to develop ROR1 CAR-T for a chronic leukemia treatment and Innovative CAR-T which can treat lung and ovarian cancer. All new CAR-T products under development are a bi-specific (dual antibody binding) CAR-T and made in a...
2022-03-25 7:57 PM EDT
Biocure Corporate Update and Financing
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2021) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("Biocure" or the "Company") is pleased to provide the following operational and investment update to the market and its stakeholders. The Company continues to build financial value within Cancer Treatment through two ways; Development of it's own pipeline products with potential for the Company to secure a number of patents covering revolutionary Car-T bi-specific therapies...
2021-12-02 9:00 AM EST
Biocure Technology Inc. Announces Focus on its own CAR T-cell Therapy Targeting Chronic Lymphocytic Leukemia ("CLL") and Solid Tumor Cancers and Intent to Apply for Patents
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2021) - BioCure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (FSE: 1WH) ("BioCure" or the "Company") is pleased to provide the following corporate update;BiocurePharm Corp. ("BPK"), a subsidiary of the Company is excited to announce its focus on the development of its own CAR T-cell therapy targeting Chronic lymphocytic leukemia and solid tumor cancers. BPK is using an innovative concept of ROR1 CAR T-cell therapy combined with a double...
2021-08-30 9:00 AM EDT
BioCure Technology Inc. Lists on the Frankfurt Stock Exchange and Completion of Issuer Sponsored Research Report
Vancouver, British Columbia--(Newsfile Corp. - August 3, 2021) - BioCure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (FSE: 1WH ) (CURE or the Company) - BioCure Technology Inc. ("BioCure" or the "Company") is pleased to announce listing on the Frankfurt Stock Exchange as of August 2, 2021 and the completion of an issuer sponsored research report by Pitt Street Research.BioCure Technology Inc. is pleased to announce that the company will begin trading on the Frankfurt Stock Exchange on August...
2021-08-03 2:27 PM EDT
BioCure Technology Inc. Announces New President, Appointment of Capital Markets Advisor and Grant of Stock Options
Vancouver, British Columbia--(Newsfile Corp. - July 22, 2021) - BioCure Technology Inc., (CSE: CURE) (OTCQB: BICTF) (CURE or the Company) is pleased to announce that Björn Cochlovius, Ph.D, Assoc.Prof., has joined BioCure Technology Inc. as President. We are also pleased to announce that Diverse Capital Pte Ltd ("Diverse Capital") has been appointed as a Capital Markets Advisor.Dr. Cochlovius brings leadership experience in multiple Management and Board positions. He has experience in...
2021-07-22 3:46 PM EDT
BioCure Technology Inc. Announces Closing of Financing
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2021) - BioCure Technology Inc. (CSE: CURE) ("BioCure" or the "Company") announces that it has successfully closed a non-brokered private placement (the "Private Placement") consisting of 6,706,525 Units at a price of $0.16 cents per Unit for gross proceeds of $1,073,044.00Each Unit is comprised of one common share (the "Shares") and one share purchase warrant (the "Warrants") of the Company, where each whole Warrant entitles the holder...
2021-07-14 8:00 PM EDT
BioCure Technology Inc. Commences Dual Listing in Germany and Announces New Contracts
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2021) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) (CURE or the Company) is pleased to announce that it has started with its dual listing on the Frankfurt Stock Exchange. As the Company is seeing increased investor interest due to its potential European partnerships with Symbasis GmbH in Germany and S&R Biopharm in Bulgaria and as it plans to move towards it's Car-T trials later this year, the Company believes the dual listing...
2021-06-28 9:00 AM EDT
BiocurePharm, Korea (BPK) Signs MOU With Symbasis GmbH to Develop CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL)
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) (CURE or the Company) BiocurePharm, Korea (BPK), a subsidiary of Biocure Technology Inc. (CURE) is pleased to announce that BPK has entered into a MOU with Symbasis GmbH. They have expressed a common interest in developing a CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL) and wish to sign this MOU for the purpose of confirming their intention in respect to the...
2021-01-04 9:00 AM EST
BiocurePharm, Korea ("BPK") Announces the Submission of IND Application for Phase 1 Trial of CD19 CAR-T Therapy
Vancouver, British Columbia--(Newsfile Corp. - December 30, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that BiocurePharm Korea ("BPK") and Pharos Vaccine Inc. ("PVI") have jointly submitted an Investigational New Drug ("IND") application to the Korean Ministry of Food and Drug Safety ("KFDS") to proceed with clinical trial Phase 1 for CD19 CAR-T...
2020-12-30 9:00 AM EST
BioCure Technology Inc. Announces Closing of Financing
Vancouver, British Columbia--(Newsfile Corp. - October 14, 2020) - BioCure Technology Inc. (CSE: CURE) ("BioCure" or the "Company") announces that it will close a non-brokered private placement (the "Private Placement") on October 15th, 2020 consisting of 1,786,725 Units at a price of $0.14 cents per Unit for gross proceeds of $250,142.Each Unit is comprised of one common share (the "Shares) and one share purchase warrant (the "Warrants") of the Company, where each whole Warrant entitles the...
2020-10-14 11:53 AM EDT
BiocurePharm, Korea ("BPK") Signs MOU With S&B Biopharm Enabling Expansion Into The European CAR T Market
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that BPK has entered into a non-binding MOU with S&B Biopharm ("SRB") located in Sofia, Bulgaria. This agreement will allow BPK to locally manufacture CD-19 CAR T in Bulgaria and sell to the Eastern European market, including Poland, Turkey and...
2020-09-21 9:15 AM EDT
BiocurePharm, Korea ("BPK") Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that they have been actively pursuing Joint Venture opportunities with several overseas companies including a strategic alliance with the University of Malaya Hospital to move forward with a compassionate human clinical trial (CT) before the end of...
2020-09-10 9:15 AM EDT
BiocurePharm, Korea ("BPK") Announces Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 5,990 shares at 12.639 CAD per share for gross proceeds of $75,707. All dollar values are based on the published Exchange...
2020-03-16 9:00 AM EDT
BiocurePharm, Korea ("BPK") Announces Private Placement
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 53,567 shares at 12.375 CAD per share for gross proceeds of $662,892. All dollar values are based on the published Exchange...
2020-01-20 9:00 AM EST
BiocurePharm, Korea ("BPK") Announces Closing of Convertible Debenture Financing
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2019) - BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that it has closed its Convertible Debenture financing. BPK has issued convertible debentures for gross proceeds of Korean Won660,000,000 (CAD732,600). Its maturity date is December 5, 2029 with the coupon rate of 3%. The investor has a right to convert to common shares...
2019-12-05 9:00 AM EST
Biocure Enters into a Clinical Trial for CAR T -Cell Products in Korea
Vancouver, British Columbia--(Newsfile Corp. - October 17, 2019) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the "Company" or "Biocure") is pleased to announce that Biocure Pharm Corp.("BPK"), a subsidiary of the Company has appointed CLIPS (Clinical Professional Services) as the CRO (Contract Research Organization) to proceed with a Clinical Trial for CAR-T products in Korea. After reviewing multiple competent CRO's in Korea and multiple meetings with them, BPK has selected CLIPS...
2019-10-17 9:00 AM EDT
CORRECTION FROM SOURCE: BiocurePharm, Korea ("BPK") Announces Closing of Convertible Debenture Financing
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2019) - Biocure Technology Corp. (CSE:CURE) (OTCQB: BICTF) ("CURE" or the "Company") wishes to correct its earlier press release of today's date to advise that it has closed its Convertible Debenture financing through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued convertible debentures for gross proceeds of Korean Won440,000,000 (CAD490,160). As previously advised, their maturity date is September 9, 2029 with...
2019-09-19 9:37 PM EDT
BiocurePharm, Korea ("BPK") Announces Closing of Convertible Debenture Financing
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2019) - BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that it has closed its Convertible Debenture financing through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 4 units at CAD111,400 per unit for gross proceeds of CAD445,600. Its maturity date is September 9, 2029 with the coupon rate of 3%. The...
2019-09-19 9:00 AM EDT
BiocurePharm, Korea ("BPK") Announces Closing of Private Placement
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 60,404 shares at $10.898 CAD per share for gross proceeds of $658,258.63 (Korean Won591,959,200 @$0.001112 CAD/KW...
2019-07-11 6:14 PM EDT